NCT05227144 - Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 6, 2022

Primary Completion Date

March 3, 2025

Study Completion Date

March 3, 2025

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

DRUG

ORIC-533

ORIC-533 once daily in consecutive 28-day cycles

Trial Locations (8)

Icahn School of Medicine at Mount Sinai, New York

The Charlotte-Mecklenburg Hospital Authority d/b/a Atrium Health, Charlotte

Northside Hospital Cancer Institute, Atlanta

Mayo Clinical Rochester, Rochester

James R. Berenson, MD, Inc., West Hollywood

Swedish Health Services, Seattle

Dana-Farber Cancer Institute, Boston

Princess Margaret Cancer Research Center/University Health Network, Toronto